293 related articles for article (PubMed ID: 15679068)
1. A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta.
Dimeglio LA; Ford L; McClintock C; Peacock M
J Pediatr Endocrinol Metab; 2005 Jan; 18(1):43-53. PubMed ID: 15679068
[TBL] [Abstract][Full Text] [Related]
2. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta.
DiMeglio LA; Peacock M
J Bone Miner Res; 2006 Jan; 21(1):132-40. PubMed ID: 16355282
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonate therapy for osteogenesis imperfecta.
Dwan K; Phillipi CA; Steiner RD; Basel D
Cochrane Database Syst Rev; 2014 Jul; (7):CD005088. PubMed ID: 25054949
[TBL] [Abstract][Full Text] [Related]
4. Bisphosphonate therapy for osteogenesis imperfecta.
Dwan K; Phillipi CA; Steiner RD; Basel D
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD005088. PubMed ID: 27760454
[TBL] [Abstract][Full Text] [Related]
5. Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta.
DiMeglio LA; Ford L; McClintock C; Peacock M
Bone; 2004 Nov; 35(5):1038-45. PubMed ID: 15542028
[TBL] [Abstract][Full Text] [Related]
6. Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta.
Shapiro JR; Thompson CB; Wu Y; Nunes M; Gillen C
Calcif Tissue Int; 2010 Aug; 87(2):120-9. PubMed ID: 20544187
[TBL] [Abstract][Full Text] [Related]
7. Bone densitometry in pediatric patients treated with pamidronate.
Grissom LE; Kecskemethy HH; Bachrach SJ; McKay C; Harcke HT
Pediatr Radiol; 2005 May; 35(5):511-7. PubMed ID: 15655696
[TBL] [Abstract][Full Text] [Related]
8. Benefits of pamidronate in children with osteogenesis imperfecta: an open prospective study.
Forin V; Arabi A; Guigonis V; Filipe G; Bensman A; Roux C
Joint Bone Spine; 2005 Jul; 72(4):313-8. PubMed ID: 16038843
[TBL] [Abstract][Full Text] [Related]
9. Intravenous bisphosphonate therapy in children with osteogenesis imperfecta.
Falk MJ; Heeger S; Lynch KA; DeCaro KR; Bohach D; Gibson KS; Warman ML
Pediatrics; 2003 Mar; 111(3):573-8. PubMed ID: 12612238
[TBL] [Abstract][Full Text] [Related]
10. Monthly intravenous alendronate treatment can maintain bone strength in osteogenesis imperfecta patients following cyclical pamidronate treatment.
Harada D; Kashiwagi H; Ueyama K; Oriyama K; Hanioka Y; Sakamoto N; Kondo K; Kishimoto K; Izui M; Nagamatsu Y; Yamada H; Tanaka H; Namba N; Seino Y
J Pediatr Endocrinol Metab; 2020 Nov; 33(11):1391-1397. PubMed ID: 33031051
[TBL] [Abstract][Full Text] [Related]
11. [Bone and joint diseases in children. Bisphosphonates in osteogenesis imperfecta].
Yamashita S
Clin Calcium; 2010 Jun; 20(6):918-24. PubMed ID: 20513950
[TBL] [Abstract][Full Text] [Related]
12. Cyclic pamidronate infusion improves bone mineralisation and reduces fracture incidence in osteogenesis imperfecta.
Lee YS; Low SL; Lim LA; Loke KY
Eur J Pediatr; 2001 Nov; 160(11):641-4. PubMed ID: 11760017
[TBL] [Abstract][Full Text] [Related]
13. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement.
Letocha AD; Cintas HL; Troendle JF; Reynolds JC; Cann CE; Chernoff EJ; Hill SC; Gerber LH; Marini JC
J Bone Miner Res; 2005 Jun; 20(6):977-86. PubMed ID: 15883638
[TBL] [Abstract][Full Text] [Related]
14. Effect of intravenous pamidronate treatment in children with osteogenesis imperfecta.
Atta I; Iqbal F; Lone SW; Ibrahim M; Khan YN; Raza J
J Coll Physicians Surg Pak; 2014 Sep; 24(9):653-7. PubMed ID: 25233970
[TBL] [Abstract][Full Text] [Related]
15. The clinical and radiological assessment of cyclic intravenous pamidronate administration in children with osteogenesis imperfecta.
Adiyaman P; Ocal G; Berberoğlu M; Evliyaoğlu O; Aycan Z; Cetinkaya E
Turk J Pediatr; 2004; 46(4):322-8. PubMed ID: 15641265
[TBL] [Abstract][Full Text] [Related]
16. Short-term efficacy of monthly pamidronate infusion in patients with osteogenesis imperfecta.
Choi JH; Shin YL; Yoo HW
J Korean Med Sci; 2007 Apr; 22(2):209-12. PubMed ID: 17449925
[TBL] [Abstract][Full Text] [Related]
17. Cyclic pamidronate therapy in children with osteogenesis imperfecta.
Salehpour S; Tavakkoli S
J Pediatr Endocrinol Metab; 2010; 23(1-2):73-80. PubMed ID: 20432809
[TBL] [Abstract][Full Text] [Related]
18. Alendronate treatment in children with osteogenesis imperfecta.
Akcay T; Turan S; Guran T; Bereket A
Indian Pediatr; 2008 Feb; 45(2):105-9. PubMed ID: 18310788
[TBL] [Abstract][Full Text] [Related]
19. ZOLEDRONIC ACID VERSUS ALENDRONATE IN THE TREATMENT OF CHILDREN WITH OSTEOGENESIS IMPERFECTA: A 2-YEAR CLINICAL STUDY.
Lv F; Liu Y; Xu X; Song Y; Li L; Jiang Y; Wang O; Xia W; Xing X
Endocr Pract; 2018 Feb; 24(2):179-188. PubMed ID: 29466057
[TBL] [Abstract][Full Text] [Related]
20. Effect of cyclical intravenous pamidronate therapy in children with osteogenesis imperfecta. Open-label study in seven patients.
Giraud F; Meunier PJ
Joint Bone Spine; 2002 Oct; 69(5):486-90. PubMed ID: 12477233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
